D. Ross Camidge, MD, PhD

D. Ross Camidge, MD, PhD, is director of thoracic oncology and the Joyce Zeff Chair in Lung Cancer Research at the University of Colorado Cancer Center.

After earning his PhD in molecular biology at the Medical Research Council Laboratory of Molecular Biology at Cambridge University, Dr Camidge completed his medical training at the University of Oxford, both in the United Kingdom. He then became the first person to double train in medical oncology and clinical pharmacology in the United Kingdom, before joining the University of Colorado in October 2005.

Dr Camidge’s main clinical and research interests are thoracic malignancies and developmental therapeutics. The discoveries that he and his team have made have changed the standard of care multiple times for the treatment of lung cancer. He has authored more than 350 academic publications, including in the Journal of Thoracic Oncology , The Lancet Oncology , and The New England Journal of Medicine .

He has received numerous awards, including the Bonnie J. Addario Lectureship Award in 2012, for which he was credited as a "Luminary in the quest to eradicate lung cancer." In 2013, he became the first physician to receive the Hank Baskett Sr. Spirit Award, for which he was credited as being "one of the leading minds in lung cancer today." In 2014, he was nationally recognized by the Quality of Life Research Center at Claremont University as an "Exemplary mentor in the positive development of junior colleagues in the profession." In 2016, the Bonnie J. Addario Lung Cancer Foundation (now known as GO2 for Lung Cancer) presented Dr Camidge with the A Breath Away From the Cure Award describing him as, "Simply one of the best in treating lung cancer today." At the 2023 World Conference of Lung Cancer, the International Association for the Study of Lung Cancer presented him with the Daniel C. Ihde Lectureship Award for Medical Oncology.

Every year since 2017, Dr Camidge has been internationally recognized as a Highly Cited Researcher ranked in the top 1% of all of clinical medicine by Clarivate Web of Science. Every year since 2019, he has ranked at the World Expert level by Expertscape for scholars writing about lung neoplasms over the past 10 years. He is also the founding national medical director of the Academic Thoracic Oncology Medical Investigators Consortium, a collaborative network of 16 US and Canadian sites conducting trials in thoracic oncology; cochair of the Elsevier ClinicalPath (formerly Via Oncology) Lung Cancer Pathways Committee; and a past member of the National Comprehensive Cancer Network Lung Cancer Committee.